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Background: Myocardial infarction (MI) often results in left ventricular (LV) remodeling followed by heart failure (HF).
It is of great clinical importance to understand the molecular mechanisms that trigger transition from compensated LV
injury to HF and to identify relevant diagnostic biomarkers. The aim of this study was to investigate gene expression in
the LV and to evaluate their reflection in peripheral blood mononuclear cells (PBMCs).
Methods: MI was induced in rats by ligation of the proximal left coronary artery. Rats with small, moderate, and large
MI size were included into the experiment two months after the operation. The development of heart failure was
estimated by echocardiography and catheterization. Microarrays were used to compare the LV and PBMCs
transcriptomes of control and experimental animals.
Results: Only rats with a large MI developed extensive LV remodeling and heart failure. 840 transcripts were altered in
LV of failing hearts, and especially numerous were those associated with the extracellular matrix. In contrast, no
significant gene expression changes were seen in LVs of rats with moderate or small MI that had compensated LV
injury. We showed that ceruloplasmin was similarly overexpressed in the heart and blood in response to HF, whereas
downregulation of tetraspanin 12 was significant only in the PBMCs.
Conclusion: A large size of infarcted area is critical for progression of LV remodeling and HF development, associated
with altered gene expression in the heart. Ceruloplasmin and tetraspanin 12 are potential convenient markers in readily
obtainable PBMCs.
Keywords: Left ventricular remodelling, Heart failure, Myocardial infarction, Extracellular matrix, Gene expression
profiling, Microarrays, Ceruloplasmin, Tetraspanin 12Background
Left ventricular (LV) remodelling is crucial in the develop-
ment of heart failure (HF) and is associated with increased
mortality after myocardial infarction (MI). It is character-
ized by complex structural alterations connected with
infarct expansion, scar formation, wall thinning, progressive
chamber dilation and hypertrophy [1]. Initially all these
changes help maintain normal cardiac function but in
time they become maladaptive and can be responsible for
systolic dysfunction and progressive decompensation of LV
[2]. LV remodelling involves numerous cellular changes,
but is essentially connected with dynamic alterations in the* Correspondence: mgora@ibb.waw.pl; atka@ibb.waw.pl
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reproduction in any medium, provided the orextracellular matrix (ECM) [3]. Proper organization and
composition of the ECM is necessary for structural (size,
shape) and mechanical (strength, contractility) support,
and also for communication between different cardiac cells
[4]. Numerous transcriptional studies have been performed
to investigate alterations in cardiac gene expression related
to the progression of heart failure [5-7]. To investigate the
mechanisms of heart failure animal models are mostly used
(rodents [8-10], dogs [11], swine [12]) as well as human
heart tissues [13,14] from patients with severe failing hearts
classified to transplantation. Studies on human HF usually
concentrate on the end-stage of heart failure and drug-
treated myocardium. Therefore, they miss factors that
uniquely mark the transition of LV hypertrophy to heart
failure, making animal heart failure models irreplaceable.td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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easily obtainable, could be used as a proxy to study changes
associated with heart diseases. Blood permeates the heart
with infiltration of leukocytes into the muscle tissue under
the certain conditions. Thus, PBMCs contribute to the
inflammatory response in the infarcted myocardium and
are also considered a source of factors crucial in matrix
remodelling, such as matrix metalloproteinase 9 [15].
The aim of the present study was to investigate gene
expression in the left ventricle in a well validated model
of post-infarcted HF and to evaluate their reflection in
PBMCs. We decided to use the rat model since it is
the most commonly used animal model of myocardial
infarction and heart failure and had convincingly been
shown to mimick the mechanisms of human HF.
Methods
Rat myocardial infarction model and samples processing
The study conformed to the Guide for the Care and Use
of Laboratory Animals by the US National Institutes of
Health (NIH publication No. 85–23, revised 1996) and
was approved by the local Ethics Committee.
Myocardial infarction (MI) was induced in 40 male
Wistar rats (275–300 g) by ligation of the proximal left
coronary artery, as described previously [16]. In brief,
rats were anaesthetised with ketamine HCl and xylazine
(100 mg/5 mg/kg body weight), left thoracotomy was
performed and a silk suture was tightly tied around the
proximal left coronary artery, approximately 2 mm from
its origin. The sham-operated group (control group, n = 6)
was subjected to the same protocol, except that the suture
was not tied.
Two months after the operation the rats were anaesthe-
tised with ketamine HCl and xylazine (75 mg/3.5 mg/kg
body weight) and echocardiography was performed to
evaluate the LV function and dimensions and to estimate
the infarct size. Later a micromanometer-tipped catheter
(Millar Instruments) was advanced through the right
carotid artery into the LV for recording of LV pressures.
Finally, the heart was dissected and blood samples were
obtained. Whole blood was collected via cardiac puncture
under anaesthesia and transferred to EDTA-K2 collection
tubes (Medlab Products, Warsaw, Poland). PBMCs
(peripheral blood mononuclear cells) were isolated by
centrifugation through HISTOPAQUE® 1083 (Sigma-
Aldrich, St Louis, MO, USA) according to the manufactur-
er's instructions and resuspended in RNAlater® Solution
(Ambion Inc., Austin, TX, USA). LV from rats with induced
MI was divided into a well visible fibrotic scar tissue
and apparently healthy myocardial tissue. For further
examinations, whole LV from sham-operated rats and
the morphologically unaffected part of LV from MI rats
were placed in RNAlater® Solution and stored at −80°C
until RNA extraction.For determination of infarct size regional LV wall motion
abnormalities were quantitated as described previously
[16]. The contractility of twelve wall segments visualized
in the midpapillary short-axis view and eleven segments
visualized in the long-axis view was graded as 1 (normal)
or 0 (abnormal) and the total wall motion index (WMI)
was calculated. Normal hearts had WMI = 23. Our previous
results [16] revealed that WMI closely correlated with
infarct size, thus post-MI rats were divided into three
groups: large MI (L-MI, ≥ 40% of LV area, n = 5), mod-
erate MI (M-MI, 20-39% of LV area, n = 6) and small MI
(S-MI, <20% of LV area, n = 6).
All results are given as means ± SEM. The statistical
significance was determined by one-way ANOVA followed
by a Dunnett test in case of significance, with the Statistica
software package (version 6.0, StatSoft, Poland). The
difference was considered significant at P < 0.05.
RNA isolation
Total RNA was isolated from PBMCs and heart samples
using MagNA Pure Compact System (Roche Diagnostics
GmbH, Germany) according to the manufacturer's rec-
ommendations. Heart tissues were homogenized using
MagNA Lyser Instrument (Roche Diagnostics GmbH,
Germany). The amount of isolated total RNA was quanti-
fied by UV absorption (Nanodrop, LabTech International,
UK). The quality of these samples was determined using
an Agilent 2100 Bioanalizer© and RNA 6000 Nano Kit
(Agilent, Santa Clara, CA, USA). For all RNA samples the
RIN (RNA integrity number) value was above eight.
cDNA microarrays
GeneChip® Rat Gene 1.0 ST Arrays (Affymetrix, Santa
Clara, CA, USA) were used. RNA from LV and PBMCs
samples obtained from L-MI and sham-operated rats were
processed according to standard Affymetrix manufacturer's
protocols. First, the samples were reverse transcribed and
amplified, then fragmented and biotinylated. Hybridization
to the GeneChips® was conducted for 16 h at 45°C. After
hybridization the microarrays were washed and stained on
a fluidics station and scanned in an Affymetrix GCS 3000
GeneArray Scanner.
Data analysis of microarrays
After a robust multiarray average (RMA) normalization
of microarray data, differences in gene expression levels
were calculated by comparing the group with myocardial
infarction with the sham-operated group. Lists of differen-
tially expressed genes, principal component analysis (PCA)
and hierarchical clustering were generated using the Partek
Genomics Suite software (Partek Inc, St. Louis, MO, USA).
The fold change (FC) of gene expression ratios ≥1.3 and
P ≤ 0.05 corrected by false discovery rate (FDR) were set
as significant criteria for heart tissue. For PBMCs the
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since alterations in RNA levels are usually lower in PBMCs
than in other tissues [17]. Results were additionally anno-
tated using Gene Annotator (http://rgd.mcw.edu/rgdweb/
ga/start.jsp) and BLAST: Basic Local Alignment Search
Tool (http://blast.ncbi.nlm.nih.gov/). Gene ontology ana-
lysis was done using the AmiGO's Term Enrichment tool
(version 1.8, http://amigo.geneontology.org) and the DA-
VID Gene Functional Classification Tool online (http://
david.abcc.ncifcrf.gov). The Ingenuity Pathways Analysis
software (IPA, Ingenuity® Systems, http://www.ingenuity.
com) was used to generate statistically relevant molecular
interaction networks associated with the lists of differen-
tially expressed genes. The raw data reported in this paper
have been deposited in the Gene Expression Omnibus
(GEO) database with the accession number GSE47495.
Quantitative real-time RT-qPCR
The real-time reverse transcription-polymerase chain
reaction (RT-qPCR) was used to validate the microarray
data. Each total RNA sample (400 ng) was reverse tran-
scribed using QuantiTect Reverse Transcription (Qiagen,
Germany) according to the manufacturer's recommenda-
tions. Primer sets for selected genes were designed using
Clone Manager Suite software; their sequences and reac-
tion conditions are available in additional files (Additional
file 1). Specificity of the amplified product was demon-
strated by melting curve analysis and agarose gel elec-
trophoresis (data not shown). Each sample was run in
triplicate in 96-well plates using LightCycler®480 and
LightCycler®480 FastStart SYBR Green I Master (Roche
Diagnostics GmbH, Germany). Quantification cycles (Cq)
were calculated using the fit point method (LightCycler®480
Software, Version 1.5 provided by Roche). The fold change
in gene expression levels, corrected by efficiency, was
analyzed using REST-MCS©-version 2 software [18].
The expression data were normalized to the reference
glyceraldehyde-3-phosphate dehydrogenase (Gapdh) and
hypoxanthine-guanine phosphoribosyltransferase (Hprt1)
genes, which in a GeNorm algorithm-based selection
[19] were the most stable among the four that we tested
(M-value; the highest M-value means the least stable
transcript): Hprt and Gapdh −0.464, TATA box binding
protein (Tbp) – 0.615, polymerase (RNA) II (DNA directed)
polypeptide A, transcript variant 2 (Polr2a) – 0.692. All
experiments (sample collection, preparation and storage,
primer design, qPCR normalization) were performed
according to the MIQE guidelines [20].
Results
Physiological characteristic of rats
Two months after MI induction rats with large MI (L-MI,
mean infarct size 49.8%) had extensive LV dilation, ejection
fraction (EF) reduction and a highly elevated left ventricularend-diastolic pressure (LVEDP), a recognized marker of
heart failure in the rat MI model (Table 1). On the other
hand the rats with small (S-MI) or moderate myocardial
infarction (M-MI) (mean infarct size 10.5% and 25.8%,
respectively) had only mild LV dilation and EF reduction,
but normal LVEDP.
This indicates that while the rats with the large MI
developed extensive LV remodelling and heart failure, the
rats with small or moderate infarction developed only
mild LV remodelling and a condition that could be called
compensated LV injury.
Microarrays results from heart tissues
The microarray data after normalization were subjected
to PCA analysis to visualize gene expression differences
between control and treated animals. The PCA plot
(Figure 1) demonstrates a distinct separation between
sham-operated rats and rats with L-MI in contrast to
animals with S-MI and M-MI, which clustered together
with the sham group.
Genes expressed differentially between groups were
determined using the cutoff criteria described in Materials
and Methods. The expression of 840 transcripts was altered
in L-MI rats 2 months after the operation. Consistent
with the results of the PCA analysis, no gene expression
differences were identified between rats with S-MI or
M-MI and the control group. From the total 840 transcripts
altered in the L-MI group, 814 (553 - upregulated, 261 -
downregulated) were supported with gene annotations pro-
vided by RefSeq, GeneBank (http://www.ncbi.nlm.nih.gov)
or Ensembl (http://www.ensembl.org). Their full list is
available in additional files (Additional file 2).
The genes identified as significantly altered in the L-MI
group were further subjected to a gene ontology analysis
(AmiGO) to find significant shared Gene Ontology terms.
Figure 2 presents only the GO terms with the most sig-
nificant p-values, whereas in additional files we present
complete results (Additional file 3). The analysis revealed
that the molecular function of these genes is essentially
connected to GO:0005488 binding and particularly to
GO:0097367 carbohydrate derivative binding, GO:0005539
glycosaminoglycan binding, GO:1901681 sulfur compound
binding, GO:0008201 heparin binding, GO:0005102 re-
ceptor binding and GO:0005515 protein binding. The
biological processes are mainly associated with response
to stimuli: GO:0010033 response to organic substance,
GO:0009611 response to wounding and GO:0070887
cellular response to chemical stimulus. Cell adhesion
GO:0007155 and small molecule metabolic process
GO:0044281 were also at the top of significantly altered
biological processes. Cellular component classification
showed that most of the differently expressed genes were
involved in GO:0005576 extracellular region (GO:0044421
extracellular region part, GO:0005615 extracellular space)
Table 1 Body weight and echocardiographic parameters
in post-myocardial infarction and sham-operated rats
2 months after surgery







BW [g] 419 ± 14 411 ± 8 424 ± 22 377 ± 4*
Infarct size [%] 0 10.5 ± 1.6*** 25.8 ± 1.6*** 49.8 ± 1.5***
LVEDD [mm2] 58.3 ± 1.0 63.8 ± 2.1 67.5 ± 1.1*** 99 ± 6.3***
LVESD [mm2] 26.5 ± 0.7 35 ± 1.5** 39.5 ± 0.8*** 76 ± 6.0***
EF [%] 54.5 ± 0.9 45.2 ± 0.7*** 41.5 ± 0.5*** 23.2 ± 2.8***
LVEDP [mm Hg] 6.0 ± 0.3 5.8 ± 0.3 6.8 ± 0.3 21.1 ± 0.5***
BW - body weight, LVEDD - left ventricular end-diastolic diameter, LVESD - left
ventricular end-systolic diameter, EF- ejection fraction, LVEDP - left ventricular
end-diastolic pressure.
Data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
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teinaceous extracellular matrix, GO:0044420 extracellular
matrix part).
Extracellular matrix remodelling is the critical event in
pathology of HF. For that reason, a focused hierarchical
clustering analysis was done for transcripts annotated as
GO:0031012 extracellular matrix (Additional file 4) to showFigure 1 Principal component analysis of left ventricular gene expres
microarray data in respect to their correlation. Sham - sham-operated; S-MI
large-size infarction.their expression profiles in LV samples from individual
rats (Figure 3). This analysis revealed a clearly distinct
gene expression profile of the selected genes in rats with
L-MI that clustered separately from the other groups. Inter-
estingly, all these genes were upregulated in the L-MI
group, with one exception - vitronectin (Vnt), although
they are involved in both ECM deposition and degradation.
Microarray results from PBMCs
PBMCs are considered to be an ideal surrogate tissue to
reflect changes occurring in major human organs [14].
Therefore, a further microarray analysis was performed
to evaluate if and how the progressive heart failure in
rats with L-MI affected the gene expression patterns in
PBMCs. Global transcriptomic profiles analysed by PCA
demonstrated a separation between the sham-operated
rats and rats with L-MI that was less clear-cut than that
found for the heart tissue (Figure 4). A list of differen-
tially expressed genes was determined with the cutoff
criteria described in Materials and Methods. The expression
of 72 (38 - upregulated, 34 - downregulated) well-annotated
transcripts was altered in PBMCs in the L-MI rats 2 months
after the operation in comparison with sham-operated
rats (Additional file 5). The AmiGO analysis showed nosion profiles. PCA plot shows the first three principal components of
- small-size infarction; M-MI - moderate-size infarction; L-MI -
Figure 2 (See legend on next page.)
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Figure 2 Enriched GO categories among differentially expressed genes in large-size infarction compared to sham-operated rats.
Expression level were determined in left ventricle. Graphs show top results for the biological process (A), molecular function (B) and cellular
component (C). In round brackets the p-value obtained from the AmiGO is shown, in square brackets the number of differentially expressed
genes related to a particular GO term.
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tional Annotation Tool identified several categories. The
molecular function of those genes is mainly connected to
GO:0005488 binding, especially GO:0005529 sugar and
GO:0005537 mannose binding. Biological processes are
associated with response to stimuli: GO:0014070 response
to organic cyclic substance and GO:0009607 response
to biotic stimulus (GO:0009617 response to bacterium
stimuli, GO:0051007 response to other organism). Cellular
component classification showed that most of those genes
were connected with GO:0016020 membrane. Complete
results are shown in Additional file 6.
A comparison of the list of differentially expressed
genes in LV tissue and PBMCs from rats with L-MI
revealed five transcripts (Klra7 - killer cell lectin-like
receptor, subfamily A, member 7; Clr7 - C-type lectin-
related protein 7; Cp - ceruloplasmin; Ptgs2 - prostaglandin-Figure 3 Heat map representing hierarchical clustering of 73 differen
(GO:0031012). Each column corresponds to a single microarray whereas e
the positive values in the gene expression and green for the negative ones
size infarction; L-MI - large-size infarction.endoperoxide synthase 2 and Tspan12 - tetraspanin 12)
similarly altered in both tissues (Additional file 7).
Validation of microarrays with RT-qPCR
Reverse transcription-qPCR was used to validate the
microarray data. Several genes important for heart
functioning were assayed and the results are demonstrated
in Tables 2 and 3.
First, to verify the main conclusion drawn from the
microarray results for LV samples, the expression levels of
genes coding for cardiac neurohormones (Nppa - natri-
uretic peptide A precursor, Nppb - natriuretic peptide B
precursor, Edn1 - endothelin 1) and the enzyme responsible
for converting pro-ANP and pro-BNP to mature ANP and
BNP (Corin - corin, a serine peptidase) were determined.
We confirmed that those genes were upregulated in the
L-MI group in contrast to the S-MI and M-MI groups,tially expressed genes related to extracellular matrix
ach row represents expression profile of a single gene. Red stand for
. Sham - sham-operated; S-MI - small-size infarction; M-MI - moderate-
Figure 4 Principal component analysis of PBMCs gene expression profiles. PCA plot shows the first three principal components of
microarray data in respect to their correlation. Sham - sham-operated; L-MI - large-size infarction.
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dial infarction progressed to heart failure.
We also tested transcript levels of other genes known to
be associated with cardiac hypertrophy and left ventricular
remodelling. Expression of these transcripts was altered
significantly in our model only in rats with a large MI.
Further, changes in the expression level of genes con-
nected with cardiac extracellular matrix were confirmed.
In addition to the genes whose upregulation was indicated
by microarray data, additional matrix metalloproteinase
and tissue inhibitor of metalloproteinase genes (Mmp9,
Mmp13, Mmp16, Mmp23, Timp3, Timp4) were checked.
The levels of the Mmp9 and Mmp13 transcripts were
close to the detection limit of the platform (Cq values
around cycle 35) in sham-operated, S-MI, and M-MI rats,
but were substantially higher (cycle 32 and 29 respectively)
in the L-MI group, indicating their up-regulation after
large infarction.
Overall, the RT-qPCR results were qualitatively consistent
with the results of the microarray analysis. However, the
RT-qPCR analysis tended to give higher up-regulation
levels than those calculated from the microarray data. The
highest change was found for periostin (Postn), osteopontin
(Spp1) and thrombospondin 4 (Thbs4) (20.8, 52.3, and
19.4 -fold, respectively).In addition, RT-qPCR was used to quantitate the five
transcripts found earlier to be differentially expressed
following HF in both heart and blood. The results are
shown in Table 3 for L-MI and in Additional file 8 for all
examined MI groups. Overexpression of ceruloplasmin
(Cp) was significant (P < 0.05) in both tissues, whereas
significant downregulation of tetraspanin 12 (Tspan12)
was confirmed in PBMCs but not in LV.
Discussion
The transition from LV injury to heart failure is poorly
understood. Only a small percentage of patients develop
heart failure immediately after MI, but with time many
more eventually progress to heart failure. What triggers
this process remains a matter of speculation. Therefore
it could be of great clinical relevance to understand the
differences between stable compensated LV injury and
heart failure at the gene expression level and to identify
potential triggers of the decompensation of compensated
LV injury.
The rat MI model has been used extensively to study
the pathophysiology of cardiovascular disease owing to
its good reproducibility and similarity to the course of the
human disease [21]. It has previously been shown in this
model that large MI results in progressive LV remodelling
Table 2 Comparison of results from microarrays and RT-qPCR
Large-MI Moderate-MI Small-MI
Results from RT-qPCR Results from microarrays Results from RT-qPCR Results from RT-qPCR
Gene symbol Fold change P-value Significance Fold change P-value Significance Fold change P-value Significance Fold change P-value Significance
Biomarkers in heart failure
End1 1.9 0.043 ** 1.3 0.005 ** −1.1 0.412 ns −1.3 0.147 ns
Nppa 19.2 0.001 *** 3.7 1.3e-5 *** 1.1 0.884 ns 1.2 0.694 ns
Nppb 2.2 0.001 *** 1.4 0.14 ns −1.1 0.849 ns −1.5 0.496 ns
Others related to cardiac hypertrophy and left ventricular remodelling
Corin 2.6 0.020 * 1.4 3e-5 *** 1 0.788 ns 1 0.934 ns
Hcn4 3.6 0.013 * 2.1 0.001 *** 1 0.951 ns −1.4 0.343 ns
Pparg −1.7 0.017 ** −1.4 1.4e-4 *** 1.1 0.643 ns 1 0.865 ns
Tgfβ1 1.4 0.071 ns 1.3 1.6e-5 *** 1.1 0.613 ns 1.1 0.712 ns
Tgfβ2 3.1 0.010 ** 2 7.8e-5 *** −1.1 0.762 ns 1 0.874 ns
ECM – Extracellular matrix components
ECM structural components
Col1a1 3.9 0.003 ** 2.3 6.1e-6 *** 1 0.767 ns 1 0.852 ns
Col1a2 2.3 0.011 ** 1.6 5e-5 *** −1.1 0.685 ns 1 0.852 ns
Col3a1 2.1 0.017 ** 1.5 1.3e-5 *** −1.1 0.579 ns 1.1 0.619 ns
Col8a1 5.1 0.001 *** 2.1 3.1e-8 *** 1 0.880 ns 1 0.390 ns
Col12a1 5.1 0.001 *** 2.9 3.4e-8 *** 1 0.912 ns −1.1 0.215 ns
Col14a1 2.4 0.001 *** 2 1.0e-7 *** 1.1 0.628 ns 1.1 0.891 ns
Col18a1 2.2 0.001 *** 1.3 7.6e-5 *** −1.1 0.668 ns −1.1 0.310 ns
Eln 2.2 0.001 *** 1.4 1.8e-5 *** 1.2 0.304 ns 1.1 0.689 ns
Fn1 3.8 0.005 ** 2.9 6.2e-8 *** 1.2 0.384 ns 1.1 0522 ns
Lamc1 1.3 0.014 ** 1.3 5.1e-7 *** 1.1 0.451 ns 1 0.773 ns
Prg4 2.1 0.004 ** 1.7 2.4e-5 *** 1 0.907 ns −1.1 0.430 ns
Vtn −1.4 0.015 * −1.4 2.3e-6 *** 1 0.874 ns −1.1 0.167 ns
Matricellular proteins
Mmp2 1.6 0.001 *** 1.4 7.5e-7 *** 1 0.855 ns 1.1 0.343 ns
Mmp9 2.7 0.351 ns † 1.73 0.037 * 1.2 0.660 ns 1 0.871 ns
Mmp13 62.2 0.001 *** † 2 0.021 * −1.2 0.358 ns 1 0.862 ns
Mmp14 2.3 0.019 ** 1.3 0.002 ** 1.1 0.529 ns −1.1 0.465 ns
Mmp16 2.9 0.020 ** 1.3 0.006 *** −1.4 0.204 ns −1.3 0.334 ns




















Table 2 Comparison of results from microarrays and RT-qPCR (Continued)
Postn 20.8 0.001 *** 8 1.2e-9 *** 1 0.988 ns 1.1 0.738 ns
Spp1 52.3 0.003 ** 4.1 2.3e-5 *** 2.7 0.157 ns 2.3 0.212 ns
Thbs4 19.4 0.003 ** 6.1 8e-9 *** −1.7 0.272 ns −1.3 0.348 ns
Timp1 3 0.008 ** 2.4 2.8e-7 *** 1.2 0.287 ns 1.4 0.041 *
Timp2 1.7 0.037 ** 1.5 4.6e-7 *** −1.1 0.666 ns 1 0.936 ns
Timp3 1.9 0.043 * 1.2 7.8e-5 *** −1.4 0.288 ns −1.3 0.321 ns
Timp4 −1.5 0.151 ns −1.4 0.006 ** −1.3 0.307 ns −1.1 0.716 ns
Expression level of selected genes was measured 2 months after operation in left ventricle tissues of all infarcted rats and compared to sham-operated group (statistical significance: *P < 0.05, **P < 0.01, ***P < 0.001,




















Table 3 Comparison of results from microarrays and RT-qPCR of genes altered similarly in LVs and PBMCs
Large-MI vs Sham in PBMCs Large-MI vs Sham in LVs
Results from RT-qPCR Results from microarrays Results from RT-qPCR Results from microarrays
Gene symbol GenBank ID Fold change P-value Fold change P-value Fold change P-value Fold change P-value
Clr7 EU128749.1 1.4 0.129ns 1.6 0.014* 1.5 0.046* 1.7 2.4e-6***
Cp NM_012532 2.3 0.039* 1.2 0.019* 3.3 0.001** 2.3 1.9e-9***
Klra7 XM_578407.4 1.6 0.112ns 1.4 0.048* 2.3 0.001** 1.2 3.3e-4***
Ptgs2 NM_017232 2.4 0.073near 1.3 0.037* 3.5 0.001** 2.2 9.9e-6***
Tspan12 NM_001015026 -3.22 0.019* -3.0 0.011* 1.1 0.734ns -1.4 8.0e-6***
Statistical significance: *P < 0.05, **P < 0.01, ***P < 0.001, ns = non significant, near = near significance. Results were normalized to Gapdh and Hprt.
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well as progressive increase of serum BNP (natriuretic
peptide B) concentration, while smaller infarctions result
in limited LV injury that is not progressive [16]. Further-
more, measurements of LV wall stress indicate that while
in large MI the wall stress progressively increases after the
infarction, in smaller infarcts its progression is stopped
fairly early after the infarction [22].
In the present study, we analyzed echocardiographic
parameters and gene expression changes in rats with a
wide range of myocardial infarct size two months after
MI induction. Both echocardiographic parameters and
expression data of well-known HF biomarkers (Nppa -
natriuretic peptide A precursor, Nppb - natriuretic pep-
tide B precursor, Edn1 - endothelin 1 [23,24]) supported
the finding that only animals with large MI developed
extensive LV remodelling and heart failure, while inter-
mediate or small MI resulted in compensated LV injury.
We confirmed a significant up-regulation of Corin gene
expression in rats with large MI that was shown earlier
for the LV myocardium of a rat model of heart failure
induced by ligation of the left coronary artery [25]. Inter-
estingly, Corin gene expression was decreased in the
atrium in HF rats [26]. Recently, levels of circulating
plasma corin were found to be diminished in patients
with heart failure, but not in patients with acute MI
[27,28]. These findings indicate that distinct expression
profiles of Corin in ventricular and atrial tissues and
reduced levels of soluble corin protein in the plasma
may be important in the pathogenesis of HF. In addition,
we noted in the failing heart a high increase of the expres-
sion levels of trombospondin 4 (Thbs4), osteopontin (Ssp1)
and periostin (Postn), in support of previously published
results indicating that these proteins could have high thera-
peutic and diagnostic potential in HF [6,29].
Analysis of transcriptome profiles revealed markedly
altered gene expression in the left ventricular tissues in
rats with large MI. In contrast, two months after MI
induction rats with moderate or small MI did not differ
significantly from the sham operated ones in this regard.
The transcripts altered in the L-MI group were relatedto diverse GO categories, of which the most striking
was upregulation of extracellular matrix genes. It is well
established that an imbalance between ECM components
and disturbances in collagen metabolism are crucial in the
progression of heart failure [30,31]. Therefore, detailed
understanding of the alterations of key matrix proteins is
essential in deciphering the mechanisms of LV remodelling
after MI.
Matrix metalloproteinases (MMPs), also known as
matrixins, are proteinases crucial in both normal tissue
remodelling (development, wound healing) and in patho-
logical conditions (arthritis, scar formation after MI, LV
remodelling). There is ample evidence that MMPs
modulate myocardial remodelling underlying heart failure
progression [32,33]. From our results Mmp2, Mmp14,
Mmp16 and Mmp23 appeared to be constitutively ex-
pressed in the heart and overexpresed in volume overload
conditions, whereas Mmp9 and Mmp13 transcripts were
abundant only in the failing heart. To the best of our
knowledge, this is the first report of an elevated expression
of Mmp16 ("membrane type", synonym MT3-MMP)
connected with heart failure. The interstitial tissue homeo-
stasis is determined by an interplay between MMPs and
their tissue post-translational inhibitors (TIMP). TIMPs not
only bind the active MMP domain, but can also interact
with the pro-MMP domain which can facilitate MMP
activity [33]. MMP/TIMP profiles can be informative in
the context of HF. Our study showed significant overex-
pression of Timp1, -2 and −3, similar to the end-stage
human heart failure [31]. An upregulation of Timp1 was
also found in studies on the transition from hypertrophy
to HF in rats [34], and an increased serum level of
TIMP1 protein was related with HF progression [35]
and mortality risk [36].
Peripheral blood mononuclear cells (PBMCs) are more
easily accessible than a tissue biopsy. Numerous studies
have shown that circulating blood cells are involved in
the pathogenesis of many diseases and may serve as
biomarkers of pathological changes occurring in other
tissues [17,37]. PBMCs also contribute to LV remodelling by
expressing key proteins, such as matrix metalloproteinase
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changes in the expression of MMPs or TIMPs in PBMCs
(data not shown), but found other gene alterations of
interest.
Our analysis indicated five HF-affected genes in the
both examined tissues, but only one - ceruloplasmin
(Cp) - showed statistically significant changes in expres-
sion (Table 3). Ceruloplasmin is a plasma metalloprotein
synthesized in hepatocytes and in activated monocytes/
macrophages and secreted into the serum, with a copper
ion incorporated during biosynthesis. It acts as an antioxi-
dant through its ferroxidase activity and also regulates
nitric oxide homeostasis in the blood plasma by converting
NO to NO2, thus an elevated level of CP may lead to de-
creased NO bioavailability and endovascular dysfunction
[38]. Ceruloplasmin level increases in various acute in-
flammatory conditions, including acute graft-versus-host-
disease (aGvHD) after allogeneic hematopoietic stem
cell transplantation [39], cancer [40], and cardiovascularFigure 5 Highest scoring interaction network generated by Ingenuity
The top network classified as “Cardiovascular System Development and Fu
Proliferation” is overlaid for cardiovascular diseases. Genes or gene product
two nodes is represented as a line. Continuous lines indicate direct interac
and downregulated genes are shown in red and green shading respective
symbols indicate molecules absent in the analysed dataset but related withdisease [41]. Recent studies indicate serum CP as an inde-
pendent cardiac risk factor [42] and show its association
with heart failure [43,44]. Our results strongly support
those findings, since large infarction in rats raised the level
of Cp mRNA in the heart and PBMCs. We showed that
both PBMCs and failing myocardium could be a major
source of ceruloplasmin that is subsequently found in
the serum of patients with heart failure. Accordingly,
we propose that CP is important in the progression of
heart failure due to its property of an acute phase pro-
tein, antioxidant function and regulation of nitric oxide
homeostasis.
Another interesting gene responding to HF was tetraspa-
nin 12 (Tspan12). In contrast to Cp, it was downregulated
substantially in the PBMCs but showed no response in
the heart tissue. Members of the tetraspanin superfamily
regulate key cellular processes such as adhesion, migration,
and fusion. Tetraspanins play particularly important roles
in cancer, by modulating tumor cell growth. TetraspaninsPathway Analysis for genes differentially expressed in PBMCs.
nction, Cellular Function and Maintenance, Cellular Growth and
s are represented as nodes, and the biological relationship between
tions, while dashed lines indicate indirect relationships. Upregulated
ly, with colour intensity related to the fold change in expression. White
the dataset genes.
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involved in both physiological and pathological processes
related to angiogenesis, vascular injury, thrombosis, and
haemostasis. Previous studies suggest that tetraspanins
directly regulate the development and functioning of the
vascular system and the pathogenesis of vascular diseases
[45]. In addition, mutations in the Tspan12 gene are
associated with familial exudative vitreoretinopathy, a
human disease caused by failure of peripheral retinal
vascularization. Our results for the first time linked
directly Tspan12 downregulation with heart failure devel-
opment. To better understand the biological relevance of
this finding we performed an Ingenuity Pathway Analysis
of the molecular interaction networks for the genes differ-
entially expressed in PBMCs. The major functional network
with the highest score (IPA score = 47) and with 20 up- or
downregulated genes, including Tspan 12, was associated
with Cardiovascular System Development and Function,
Cellular Function and Maintenance, Cellular Growth and
Proliferation (Figure 5). This network analysis indicates that
altered expression of tetraspanin 12 and other identified
molecules may result in a dysfunction of the cardiovascular
system by disturbance of their direct and indirect func-
tional interactions. Moreover, tetraspanin 12 was found
recently to regulate the activity of membrane metallopro-
teinases, MT1-MMP/MMP14 [46] and ADAM10 (disinte-
grin and metalloproteinase domain-containing protein 10)
[47]. Affected functions of MT1-MMP/MMP14 influence
fibronectin proteolysis and extracellular matrix degradation.
ADAM10 is responsible for the proteolytic release of the
ectodomains of numerous protein substrates, including
specific ligands of EGFR (epidermal growth factor receptor)
regulating the subsequent EGFR-dependent signal trans-
duction pathways involved in cardiac hypertrophy [48].
Interestingly, ADAM10 mediates also cleavage of corin
that may be important in regulating corin activity and
hence ANP processing [49].
On the other hand, it is well known that heart remodel-
ing after myocardial infarction, especially after a large one,
is accompanied by extensive neurohumoral activation. An
increased plasma norepinephrine concentration due to
a marked increase in the sympathetic nerve activity is a
common finding in experimental heart failure models
as well as in humans. Moreover, the increased wall
stress after myocardial infarction and increased plasma
norepinephrine level result in the activation of the
renin-angiotensin-aldosteron system (RAAS) followed
by an increase of the renin and angiotensin II plasma
levels. Additionally, increased levels of vasopressin and
endothelin have been found in heart failure. [50]. It is
possible that these neurohormones circulating in the
plasma could influence the expression of diverse genes
in PMBCs through activation of the receptors present on
the surface of these cells. Besides, PBMCs are mononuclearcells recruited into the infarcted myocardium [15] and the
invading monocytes differentiate into macrophages also
during tissue repair after myocardial infarction [51].
We therefore hypothesize that the altered expression
of Tspan12 in PBMCs may influence the pathological
processes occurring in the failing heart, especially that
tetraspanins are present not only on the plasma membrane
but also in exosomes, which are often released by cells as
messenger vehicles for intercellular communication [52].Conclusions
We showed that a large size of infarcted area is critical
for progression of LV remodelling and HF development,
associated with altered gene expression in the heart. In
contrast, compensated LV injury does not lead to significant
changes of the transcriptome as evaluated two months after
the injury. Transcriptional profiling of failing myocardium
and peripheral blood mononuclear cells simultaneously is
a useful approach for robust markers of heart failure.
We identified genes (Cp, Tspan12) whose expression is
altered in the readily obtainable blood cells in response
to progressive heart failure. To our knowledge, this is the
first report on a possible association of Tspan12 expression
with HF development.Additional files
Additional file 1: Primer sequences and parameters used to
validate the microarray analysis by RT-qPCR.
Additional file 2: Transcripts differentially expressed in LVs
between rats with large-sized infarction and sham-operated ones.
Additional file 3: AmiGO Term Enrichment analysis of differentially
expressed transcripts in LVs between rats with large-size of infarction
and sham-operated ones.
Additional file 4: Differentially expressed genes related to
GO:0031012: extracellular matrix.
Additional file 5: Transcripts differentially expressed in PBMCs
between rats with large-size of infarction and sham-operated ones.
Additional file 6: Chart report from DAVID analysis to determine
GO term enrichment of BP (biological process), MF (molecular
function) and CC (cellular component) and their associated
genes differentially expressed in PBMCs between L-MI and sham
operated group.
Additional file 7: Genes that were altered similarly in LVs and
PBMCs - microarray results.
Additional file 8: Comparison of results from RT-qPCR of genes that
were altered similarly in LVs and PBMCs.Competing interests
The authors declare that they have no competing interests.
Author’ contributions
MG, BB, UM and MM conceived and designed the experiments. UM, MM
carried out the animal work and co-wrote the paper. MG and BB performed
the microarray experiments. DT and AM performed the RT-qPCR experi-
ments. DT analyzed the data and wrote the paper. MG, BB critically reviewed
the manuscript. All authors read and approved the final manuscript.
Tulacz et al. BMC Medical Genomics 2013, 6:49 Page 13 of 14
http://www.biomedcentral.com/1755-8794/6/49Acknowledgements
We are grateful to the Laboratory of Microarray Analysis of Center of
Excellence BioExploratorium (Department of Biology Warsaw University and
Institute of Biochemistry and Biophysics PAS, Warsaw, Poland) for possibility
of using the Affymetrix microarray platform. We thank Monika Niewiadomska
for technical assistance in samples collection. This work was supported by
The National Centre for Research and Development, Poland [N R13 0001 06].
Author details
1Institute of Biochemistry and Biophysics Polish Academy of Sciences,
Pawinskiego 5a, 02-106 Warsaw, Poland. 2Department of Clinical Physiology,
Medical Centre of Postgraduate Education, Marymoncka 99/103, 02-813
Warsaw, Poland.
Received: 26 July 2013 Accepted: 1 November 2013
Published: 8 November 2013References
1. Sutton MG, Sharpe N: Left ventricular remodeling after myocardial
infarction: pathophysiology and therapy. Circulation 2000,
101:2981–2988.
2. Takano H, Hasegawa H, Nagai T, Komuro I: Implication of cardiac
remodeling in heart failure: mechanisms and therapeutic strategies.
Intern Med 2003, 42:465–469.
3. Dobaczewski M, Gonzalez-Quesada C, Frangogiannis NG: The extracellular
matrix as a modulator of the inflammatory and reparative response
following myocardial infarction. J Mol Cell Cardiol 2010, 48:504–511.
4. Okamoto H, Imanaka-Yoshida K: Matricellular proteins: new molecular
targets to prevent heart failure. Cardiovasc Ther 2012, 30:e198–209.
5. Sharma UC, Pokharel S, Evelo CT, Maessen JG: A systematic review of large
scale and heterogeneous gene array data in heart failure. J Mol Cell
Cardiol 2005, 38:425–432.
6. Asakura M, Kitakaze M: Global gene expression profiling in the failing
myocardium. Circ J 2009, 73:1568–1576.
7. Schwientek P, Ellinghaus P, Steppan S, D'Urso D, Seewald M, Kassner A,
Cebulla R, Schulte-Eistrup S, Morshuis M, Röfe D, El Banayosy A, Körfer R,
Milting H: Global gene expression analysis in nonfailing and failing
myocardium pre- and postpulsatile and nonpulsatile ventricular assist
device support. Physiol Genomics 2010, 42:397–405.
8. Jin H, Yang R, Awad TA, Wang F, Li W, Williams SP, Ogasawara A, Shimada
B, Williams PM, de Feo G, Paoni NF: Effects of early angiotensin-converting
enzyme inhibition on cardiac gene expression after acute myocardial
infarction. Circulation 2001, 103:736–742.
9. Brooks WW, Shen S, Conrad CH, Goldstein RH, Deng LL, Bing OH:
Transcriptional changes associated with recovery from heart failure in
the SHR. J Mol Cell Cardiol 2010, 49:390–401.
10. Azuaje F, Zhang L, Jeanty C, Puhl SL, Rodius S, Wagner DR: Analysis of a
gene co-expression network establishes robust association between
Col5a2 and ischemic heart disease. BMC Med Genomics 2013, 6:13.
11. Ojaimi C, Qanud K, Hintze TH, Recchia FA: Altered expression of a limited
number of genes contributes to cardiac decompensation during chronic
ventricular tachypacing in dogs. Physiol Genomics 2007, 29:76–83.
12. Prat-Vidal C, Gálvez-Montón C, Nonell L, Puigdecanet E, Astier L, Solé F,
Bayes-Genis A: Identification of temporal and region-specific myocardial
gene expression patterns in response to infarction in swine. PLoS One
2013, 8:e54785.
13. Tan Tan FL, Moravec CS, Li J, Apperson-Hansen C, McCarthy PM, Young JB,
Bond M: The gene expression fingerprint of human heart failure. Proc
Natl Acad Sci U S A 2002, 99:11387–11392.
14. Felkin LE, Lara-Pezzi EA, Hall JL, Birks EJ, Barton PJ: Identification of genes
related to heart failure using global gene expression profiling of human
failing myocardium. Biochem Biophys Res Commun 2010, 393:55–60.
15. Fang L, Du XJ, Gao XM, Dart AM: Activation of peripheral blood
mononuclear cells and extracellular matrix and inflammatory gene
profile in acute myocardial infarction. Clin Sci (Lond) 2010, 119:175–183.
16. Maczewski M, Maczewska J: Hypercholesterolemia exacerbates ventricular
remodeling in the rat model of myocardial infarction. J Card Fail 2006,
12:399–405.
17. Mohr S, Liew CC: The peripheral-blood transcriptome: new insights into
disease and risk assessment. Trends Mol Med 2007, 13:422–432.18. Pfaffl MW, Horgan GW, Dempfle L: Relative expression software tool
(REST) for group-wise comparison and statistical analysis of relative
expression results in real-time PCR. Nucleic Acids Res 2002, 30:e36.
19. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A,
Speleman F: Accurate normalization of real-time quantitative RT-PCR data
by geometric averaging of multiple internal controlgenes. Genome Biol
2002, 18:3(7).
20. Taylor S, Wakem M, Dijkman G, Alsarraj M, Nguyen M: A practical approach
to RT-qPCR-Publishing data that conform to the MIQE guidelines.
Methods 2010, 50(4):S1–5.
21. Pfeffer MA, Janice M: Memorial lecture. J of Card Fail 2002,
8(6 Suppl):S248–S252.
22. Mackiewicz U, Maczewski M, Klemenska E, Brudek M, Konior A, Czarnowska
E, Lewartowski BJ: Brief postinfarction calcineurin blockade affects left
ventricular remodeling and Ca2+ handling in the rat. Mol Cell Cardiol
2010, 48:1307–1315.
23. Calvieri C, Rubattu S, Volpe M: Molecular mechanisms underlying cardiac
antihypertrophic and antifibrotic effects of natriuretic peptides. J Mol
Med (Berl) 2012, 90:5–13.
24. Tønnessen T, Christensen G, Oie E, Holt E, Kjekshus H, Smiseth OA, Sejersted
OM, Attramadal H: Increased cardiac expression of endothelin-1 mRNA in
ischemic heart failure in rats. Cardiovasc Res 1997, 33:601–610.
25. Tran KL, Lu X, Lei M, Feng Q, Wu Q: Upregulation of corin gene
expression in hypertrophic cardiomyocytes and failing myocardium.
Am J Physiol Heart Circ Physiol 2004, 287:H1625–H631.
26. Langenickel TH, Pagel I, Buttgereit J, Tenner K, Lindner M, Dietz R,
Willenbrock R, Bader M: Rat corin gene: molecular cloning and reduced
expression in experimental heart failure. Am J Physiol Heart Circ Physiol
2004, 287:H1516–H1521.
27. Dong N, Chen S, Wang W, Zhou Y, Wu Q: Corin in clinical laboratory
diagnostics. Clin Chim Acta 2012, 413:378–383.
28. Ibebuogu UN, Gladysheva IP, Houng AK, Reed GL: Decompensated heart
failure is associated with reduced corin levels and decreased cleavage of
pro-atrial natriuretic peptide. Circ Heart Fail 2011, 4:114–120.
29. Schipper ME, Scheenstra MR, van Kuik J, van Wichen DF, van der Weide P,
Dullens HF, Lahpor J, de Jonge N, De Weger RA: Osteopontin: a potential
biomarker for heart failure and reverse remodeling after left ventricular
assist device support. J Heart Lung Transplant 2011, 30:805–810.
30. Fomovsky GM, Thomopoulos S, Holmes JW: Contribution of extracellular
matrix to the mechanical properties of the heart. J Mol Cell Cardiol 2010,
48:490–496.
31. Polyakova V, Loeffler I, Hein S, Miyagawa S, Piotrowska I, Dammer S, Risteli J,
Schaper J, Kostin S: Fibrosis in endstage human heart failure: severe
changes in collagen metabolism and MMP/TIMP profiles. Int J Cardiol
2011, 151:18–33.
32. Graham HK, Horn M, Trafford AW: Extracellular matrix profiles in the
progression to heart failure. European Young Physiologists Symposium
Keynote Lecture-Bratislava 2007. Acta Physiol (Oxf ) 2008, 194:3–21.
33. Spinale FG, Janicki JS, Zile MR: Membrane-associated matrix proteolysis
and heart failure. Circ Res 2013, 112:195–208.
34. Rysä J, Leskinen H, Ilves M, Ruskoaho H: Distinct upregulation of
extracellular matrix genes in transition from hypertrophy to
hypertensive heart failure. Hypertension 2005, 45:927–933.
35. Spinale FG, Gunasinghe H, Sprunger PD, Baskin JM, Bradham WC:
Extracellular degradative pathways in myocardial remodeling and
progression to heart failure. J Card Fail 2002, 8:S332–S338.
36. Hansson J, Vasan RS, Ärnlöv J, Ingelsson E, Lind L, Larsson A, Michaëlsson K,
Sundström J: Biomarkers of extracellular matrix metabolism (MMP-9 and
TIMP-1) and risk of stroke, myocardial infarction, and cause-specific mor-
tality: cohort study. PLoS ONE 2011, 6:e16185.
37. Devaux Y, Bousquenaud M, Rodius S, Marie PY, Maskali F, Zhang L, Azuaje F,
Wagner DR: Transforming growth factor β receptor 1 is a new candidate
prognostic biomarker after acute myocardial infarction. BMC Med
Genomics 2011, 4:83.
38. Shiva S, Wang X, Ringwood LA, Xu X, Yuditskaya S, Annavajjhala V, Miyajima H,
Hogg N, Harris ZL, Gladwin MT: Ceruloplasmin is a NO oxidase and nitrite
synthase that determines endocrine NO homeostasis. Nat Chem Biol 2006,
2:486–493.
39. Lv M, Ye HG, Zhao XS, Zhao XY, Chang YJ, Liu DH, Xu LP, Huang XJ:
Ceruloplasmin is a potential biomarker for aGvHD following allogeneic
hematopoietic stem cell transplantation. PLoS One 2013, 8:e58735.
Tulacz et al. BMC Medical Genomics 2013, 6:49 Page 14 of 14
http://www.biomedcentral.com/1755-8794/6/4940. Huang H, Li Y, Liu J, Zheng M, Feng Y, Hu K, Huang Y, Huang Q: Screening
and identification of biomarkers in ascites related to intrinsic
chemoresistance of serous epithelial ovarian cancers. PLoS One 2012,
7:e51256.
41. Giurgea N, Constantinescu MI, Stanciu R, Suciu S, Muresan A: Ceruloplasmin -
acute-phase reactant or endogenous antioxidant? The case of
cardiovascular disease. Med Sci Monit 2005, 11:RA48–RA51.
42. Wu Y, Hartiala J, Fan Y, Stewart AF, Roberts R, McPherson R, Fox PL, Allayee
H, Hazen SL: Clinical and genetic association of serum ceruloplasmin
with cardiovascular risk. Arterioscler Thromb Vasc Biol 2012, 32:516–522.
43. Xu Y, Lin H, Zhou Y, Cheng G, Xu G: Ceruloplasmin and the extent of
heart failure in ischemic and nonischemic cardiomyopathy patients.
Mediators Inflamm 2013, 2013:348145.
44. Dadu RT, Dodge R, Nambi V, Virani SS, Hoogeveen RC, Smith NL, Chen F,
Pankow JS, Guild C, Tang WH, Boerwinkle E, Hazen SL, Ballantyne CM:
Ceruloplasmin and heart failure in the atherosclerosis risk in
communities study. Circ Heart Fail 2013, 6(5):936–943.
45. Zhang F, Kotha J, Jennings LK, Zhang XA: Tetraspanins and vascular
functions. Cardiovasc Res 2009, 83:7–15.
46. Lafleur MA, Xu D, Hemler ME: Tetraspanin proteins regulate membrane
type-1 matrix metalloproteinase-dependent pericellular proteolysis. Mol
Biol Cell 2009, 20(7):2030–2040.
47. Xu D, Sharma C, Hemler ME: Tetraspanin12 regulates ADAM10-dependent
cleavage of amyloid precursor protein. FASEB J 2009, 23(11):3674–3681.
48. Chan HW, Smith NJ, Hannan RD, Thomas WG: Tackling the EGFR in
pathological tissue remodelling. Pulm Pharmacol Ther 2006, 19(1):74–78.
49. Jiang J, Wu S, Wang W, Chen S, Peng J, Zhang X, Wu Q: Ectodomain
shedding and -autocleavage of the cardiac membrane protease corin.
J Biol Chem 2011, 286(12):10066–10072.
50. Mancia G: Neurohumoral activation in congestive heart failure. Am Heart
J 1990, 120(6 Pt 2):1532–1537.
51. Troidl C, Möllmann H, Nef H, Masseli F, Voss S, Szardien S, Willmer M, Rolf A,
Rixe J, Troidl K, Kostin S, Hamm C, Elsässer A: Classically and alternatively
activated macrophages contribute to tissue remodelling after
myocardial infarction. J Cell Mol Med 2009, 13(9B):3485–3496.
52. Yáñez-Mó M, Gutiérrez-López MD, Cabañas C: Functional interplay
between tetraspanins and proteases. Cell Mol Life Sci 2011,
68(20):3323–3335.
doi:10.1186/1755-8794-6-49
Cite this article as: Tulacz et al.: Transcriptional profiling of left ventricle
and peripheral blood mononuclear cells in a rat model of postinfarction
heart failure. BMC Medical Genomics 2013 6:49.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
